Canaccord Genuity Group Reiterates Buy Rating for Cibus (NASDAQ:CBUS)

Cibus (NASDAQ:CBUS)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity Group in a note issued to investors on Monday,Benzinga reports. They presently have a $15.00 target price on the stock.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cibus in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.00.

Cibus Stock Up 6.3%

Shares of CBUS stock opened at $1.69 on Monday. The business has a 50-day moving average price of $1.44 and a two-hundred day moving average price of $1.54. Cibus has a 12-month low of $1.09 and a 12-month high of $4.64. The firm has a market cap of $91.73 million, a P/E ratio of -0.52 and a beta of 1.62.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). The firm had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $1.39 million. Cibus had a negative net margin of 3,133.92% and a negative return on equity of 133.90%. As a group, research analysts expect that Cibus will post -2.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Cibus

A number of large investors have recently added to or reduced their stakes in CBUS. Rockland Trust Co. purchased a new position in shares of Cibus in the third quarter valued at about $26,000. Blair William & Co. IL bought a new stake in shares of Cibus in the first quarter worth about $28,000. Qube Research & Technologies Ltd purchased a new position in Cibus during the 2nd quarter valued at about $39,000. Warberg Asset Management LLC purchased a new position in Cibus during the 2nd quarter valued at about $41,000. Finally, FNY Investment Advisers LLC purchased a new position in Cibus during the 2nd quarter valued at about $54,000. Institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.